Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke / TIA

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NĪMES · Jan 20, 2016

Keywords

ClinConnect Summary

This clinical trial is exploring two different ways to use imaging tests after a patient has experienced a stroke or a transient ischemic attack (TIA), which is often referred to as a mini-stroke. The goal is to see which method is better at finding important health issues that may need specific treatments. One method is the usual imaging approach used in hospitals, while the other starts with a special low-dose whole-body angiography, which is a type of scan that looks at blood vessels throughout the body. After this initial scan, doctors may use other tests if needed.

To participate in this study, individuals must be aged between 65 and 75, have had a stroke or TIA within the last 10 days, and be able to commit to follow-ups for 36 months. They must also understand the study and give their consent to participate. It’s important to note that some people may not be eligible, including those who are pregnant, those with certain health conditions, or those currently involved in other research studies. Participants will be monitored closely throughout the study, and their involvement could help improve care for future stroke patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The patient was informed about the implementation of the study, its objectives, constraints and patient rights
• • The patient has given free and informed consent and signed the consent
• • Patient affiliated with or beneficiary of a health insurance plan
• • Patient available for 36 months of follow-up
• • The patient has had a stroke (within the past 10 days, diagnosis confirmed by MRI with a diffusion sequence) or transient ischemic attack (within the past 10 days, ABCD2 score greater than 3) without haemorrhage
• Exclusion Criteria:
• • The patient is currently participating in or has participated in another biomedical research study within the past three months or is currently in an exclusion period determined by a previous study.
• • Patient under guardianship or judicial protection
• • Refusal to sign the consent
• • Inability to correctly inform the patient or his/her trusted person about the study
• • The patient is pregnant, parturient, or breastfeeding
• • The patient has a contraindication for a treatment used in this study
• • Known allergy to contrast medium or severe allergy to iodine
• • Known active malignancy or history of cancer treatment
• • The patient has already undergone a full body scanner in the previous three months
• • Renal failure with creatinine clearance below 60 ml / min
• • Monoclonal immunoglobulin
• • History of severe symptomatic cardiovascular event (myocardial infarction, aortic dissection, mesenteric ischemia, renal ischemia)
• • Emergency situations that hamper the planned course of the study